BUZZ-20/20 Biolabs jumps on Ebola, hantavirus testing plans

20/20 Biolabs, Inc.
Statera Biopharma, Inc. - Common Stock

20/20 Biolabs, Inc.

AIDX

0.00

Statera Biopharma, Inc. - Common Stock

STAB

0.00

** Shares of diagnostics firms 20/20 Biolabs AIDX.O rise 20% to $1.49 premarket

** Co says it is preparing plans to offer Ebola and hantavirus testing if public health agencies need support

** Co is leveraging its COVID-19 testing experience to expand into these infectious disease tests

** AIDX cautioned that no test is ready yet and that regulatory approval would still be required before any test could be used clinically

** As of last close, AIDX down ~95% since its Nasdaq debut on February 19


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.